Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 2125 entries
Sorted by: Best Match Show Resources per page
Automated multi-parameter measurement of cardiomyocytes dynamics with digital holographic microscopy.

Optics express

Rappaz B, Moon I, Yi F, Javidi B, Marquet P, Turcatti G.
PMID: 26074583
Opt Express. 2015 May 18;23(10):13333-47. doi: 10.1364/OE.23.013333.

Compounds tested during drug development may have adverse effects on the heart; therefore all new chemical entities have to undergo extensive preclinical assessment for cardiac liability. Conventional intensity-based imaging techniques are not robust enough to provide detailed information for...

Cite
Rappaz B, Moon I, Yi F, et al. Automated multi-parameter measurement of cardiomyocytes dynamics with digital holographic microscopy. Opt Express. 2015;23(10):13333-47doi: 10.1364/OE.23.013333.
Rappaz, B., Moon, I., Yi, F., Javidi, B., Marquet, P., & Turcatti, G. (2015). Automated multi-parameter measurement of cardiomyocytes dynamics with digital holographic microscopy. Optics express, 23(10), 13333-47. https://doi.org/10.1364/OE.23.013333
Rappaz, Benjamin, et al. "Automated multi-parameter measurement of cardiomyocytes dynamics with digital holographic microscopy." Optics express vol. 23,10 (2015): 13333-47. doi: https://doi.org/10.1364/OE.23.013333
Rappaz B, Moon I, Yi F, Javidi B, Marquet P, Turcatti G. Automated multi-parameter measurement of cardiomyocytes dynamics with digital holographic microscopy. Opt Express. 2015 May 18;23(10):13333-47. doi: 10.1364/OE.23.013333. PMID: 26074583.
Copy Download .nbib Format: NLM
Experiences from Garbha-Swasthya helpline.

Indian journal of public health

Godbole KG, Kulkarni SS, Godbole GP, Kulkarni AM.
PMID: 26021655
Indian J Public Health. 2015 Apr-Jun;59(2):149-52. doi: 10.4103/0019-557X.157538.

Garbha-Swasthya helpline is a telephone helpline run by a tertiary care private hospital to address issues related to pregnancy and its complications. A review of the helpline data from September 2010 to December 2012 was conducted to study caller...

Cite
Godbole KG, Kulkarni SS, Godbole GP, et al. Experiences from Garbha-Swasthya helpline. Indian J Public Health. 2015;59(2):149-52doi: 10.4103/0019-557X.157538.
Godbole, K. G., Kulkarni, S. S., Godbole, G. P., & Kulkarni, A. M. (2015). Experiences from Garbha-Swasthya helpline. Indian journal of public health, 59(2), 149-52. https://doi.org/10.4103/0019-557X.157538
Godbole, Koumudi G, et al. "Experiences from Garbha-Swasthya helpline." Indian journal of public health vol. 59,2 (2015): 149-52. doi: https://doi.org/10.4103/0019-557X.157538
Godbole KG, Kulkarni SS, Godbole GP, Kulkarni AM. Experiences from Garbha-Swasthya helpline. Indian J Public Health. 2015 Apr-Jun;59(2):149-52. doi: 10.4103/0019-557X.157538. PMID: 26021655.
Copy Download .nbib Format: NLM
Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?.

Expert review of clinical pharmacology

Kalgutkar AS, Fate G, Didiuk MT, Bauman J.
PMID: 24410554
Expert Rev Clin Pharmacol. 2008 Jul;1(4):515-31. doi: 10.1586/17512433.1.4.515.

It is generally accepted that bioactivation of relatively inert functional groups (toxicophores) to reactive metabolites is an obligatory step in the pathogenesis of certain idiosyncratic adverse drug reactions (IADRs). IADRs cannot be detected in regulatory animal toxicity studies and,...

Cite
Kalgutkar AS, Fate G, Didiuk MT, et al. Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?. Expert Rev Clin Pharmacol. 2008;1(4):515-31doi: 10.1586/17512433.1.4.515.
Kalgutkar, A. S., Fate, G., Didiuk, M. T., & Bauman, J. (2008). Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?. Expert review of clinical pharmacology, 1(4), 515-31. https://doi.org/10.1586/17512433.1.4.515
Kalgutkar, Amit S, et al. "Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?." Expert review of clinical pharmacology vol. 1,4 (2008): 515-31. doi: https://doi.org/10.1586/17512433.1.4.515
Kalgutkar AS, Fate G, Didiuk MT, Bauman J. Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?. Expert Rev Clin Pharmacol. 2008 Jul;1(4):515-31. doi: 10.1586/17512433.1.4.515. PMID: 24410554.
Copy Download .nbib Format: NLM
PRESCRIBING AND RESEARCH IN MEDICINES MANAGEMENT (UK & IRELAND) CONFERENCE 2015 IMPERIAL HOTEL LONDON JANUARY 23.

Pharmacoepidemiology and drug safety

[No authors listed]
PMID: 26075570
Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):O15-O44. doi: 10.1002/pds.3812. Epub 2015 Jun 15.

No abstract available.

Cite
PRESCRIBING AND RESEARCH IN MEDICINES MANAGEMENT (UK & IRELAND) CONFERENCE 2015 IMPERIAL HOTEL LONDON JANUARY 23. Pharmacoepidemiol Drug Saf. 2015;27(7):O15-O44doi: 10.1002/pds.3812.
(2018). PRESCRIBING AND RESEARCH IN MEDICINES MANAGEMENT (UK & IRELAND) CONFERENCE 2015 IMPERIAL HOTEL LONDON JANUARY 23. Pharmacoepidemiology and drug safety, 27(7), O15-O44. https://doi.org/10.1002/pds.3812
"PRESCRIBING AND RESEARCH IN MEDICINES MANAGEMENT (UK & IRELAND) CONFERENCE 2015 IMPERIAL HOTEL LONDON JANUARY 23." Pharmacoepidemiology and drug safety vol. 27,7 (2018): O15-O44. doi: https://doi.org/10.1002/pds.3812
PRESCRIBING AND RESEARCH IN MEDICINES MANAGEMENT (UK & IRELAND) CONFERENCE 2015 IMPERIAL HOTEL LONDON JANUARY 23. Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):O15-O44. doi: 10.1002/pds.3812. Epub 2015 Jun 15. PMID: 26075570.
Copy Download .nbib Format: NLM
Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash.

Therapeutics and clinical risk management

Weiss L, Gary D, Swern AS, Freeman J, Sugrue MM.
PMID: 26379438
Ther Clin Risk Manag. 2015 Sep 04;11:1355-60. doi: 10.2147/TCRM.S86449. eCollection 2015.

BACKGROUND: Lenalidomide is approved for treating transfusion-dependent anemia due to lower-risk del(5q) myelodysplastic syndromes (MDS). In clinical trials, rash was common, although severe rash was infrequent. To examine rash in patients with MDS treated with lenalidomide in the real...

Cite
Weiss L, Gary D, Swern AS, et al. Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash. Ther Clin Risk Manag. 2015;11:1355-60doi: 10.2147/TCRM.S86449.
Weiss, L., Gary, D., Swern, A. S., Freeman, J., & Sugrue, M. M. (2015). Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash. Therapeutics and clinical risk management, 111355-60. https://doi.org/10.2147/TCRM.S86449
Weiss, Lilia, et al. "Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash." Therapeutics and clinical risk management vol. 11 (2015): 1355-60. doi: https://doi.org/10.2147/TCRM.S86449
Weiss L, Gary D, Swern AS, Freeman J, Sugrue MM. Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash. Ther Clin Risk Manag. 2015 Sep 04;11:1355-60. doi: 10.2147/TCRM.S86449. eCollection 2015. PMID: 26379438; PMCID: PMC4567225.
Copy Download .nbib Format: NLM
Clinical Trial Electronic Portals for Expedited Safety Reporting: Recommendations from the Clinical Trials Transformation Initiative Investigational New Drug Safety Advancement Project.

JMIR cancer

Perez RP, Finnigan S, Patel K, Whitney S, Forrest A.
PMID: 28410179
JMIR Cancer. 2016 Dec 15;2(2):e16. doi: 10.2196/cancer.6701.

BACKGROUND: Use of electronic clinical trial portals has increased in recent years to assist with sponsor-investigator communication, safety reporting, and clinical trial management. Electronic portals can help reduce time and costs associated with processing paperwork and add security measures;...

Cite
Perez RP, Finnigan S, Patel K, et al. Clinical Trial Electronic Portals for Expedited Safety Reporting: Recommendations from the Clinical Trials Transformation Initiative Investigational New Drug Safety Advancement Project. JMIR Cancer. 2016;2(2):e16doi: 10.2196/cancer.6701.
Perez, R. P., Finnigan, S., Patel, K., Whitney, S., & Forrest, A. (2016). Clinical Trial Electronic Portals for Expedited Safety Reporting: Recommendations from the Clinical Trials Transformation Initiative Investigational New Drug Safety Advancement Project. JMIR cancer, 2(2), e16. https://doi.org/10.2196/cancer.6701
Perez, Raymond P, et al. "Clinical Trial Electronic Portals for Expedited Safety Reporting: Recommendations from the Clinical Trials Transformation Initiative Investigational New Drug Safety Advancement Project." JMIR cancer vol. 2,2 (2016): e16. doi: https://doi.org/10.2196/cancer.6701
Perez RP, Finnigan S, Patel K, Whitney S, Forrest A. Clinical Trial Electronic Portals for Expedited Safety Reporting: Recommendations from the Clinical Trials Transformation Initiative Investigational New Drug Safety Advancement Project. JMIR Cancer. 2016 Dec 15;2(2):e16. doi: 10.2196/cancer.6701. PMID: 28410179; PMCID: PMC5367842.
Copy Download .nbib Format: NLM
The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients.

Expert opinion on drug metabolism & toxicology

Tverdohleb T, Dinc B, Knezevic I, Candido KD, Knezevic NN.
PMID: 27388970
Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1303-1311. doi: 10.1080/17425255.2016.1209482. Epub 2016 Jul 15.

INTRODUCTION: Pharmacogenomics is the field that studies an individualized treatment approach for patients' medication regimen that can impact drug safety, productivity, and personalized health care. Pharmacogenomics characterizes the genetic differences in metabolic pathways which can affect a patient's individual...

Cite
Tverdohleb T, Dinc B, Knezevic I, et al. The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Expert Opin Drug Metab Toxicol. 2016;12(11):1303-1311doi: 10.1080/17425255.2016.1209482.
Tverdohleb, T., Dinc, B., Knezevic, I., Candido, K. D., & Knezevic, N. N. (2016). The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Expert opinion on drug metabolism & toxicology, 12(11), 1303-1311. https://doi.org/10.1080/17425255.2016.1209482
Tverdohleb, Tatiana, et al. "The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients." Expert opinion on drug metabolism & toxicology vol. 12,11 (2016): 1303-1311. doi: https://doi.org/10.1080/17425255.2016.1209482
Tverdohleb T, Dinc B, Knezevic I, Candido KD, Knezevic NN. The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1303-1311. doi: 10.1080/17425255.2016.1209482. Epub 2016 Jul 15. PMID: 27388970.
Copy Download .nbib Format: NLM
MicroRNAs in Drug-induced Liver Injury.

Journal of clinical and translational hepatology

Li LM, Wang D, Zen K.
PMID: 26357624
J Clin Transl Hepatol. 2014 Sep;2(3):162-9. doi: 10.14218/JCTH.2014.00015. Epub 2014 Sep 15.

Drug-induced liver injury (DILI) is a leading cause of acute liver failure, and a major reason for the recall of marketed drugs. Detection of potential liver injury is a challenge for clinical management and preclinical drug safety studies, as...

Cite
Li LM, Wang D, Zen K. MicroRNAs in Drug-induced Liver Injury. J Clin Transl Hepatol. 2014;2(3):162-9doi: 10.14218/JCTH.2014.00015.
Li, L. M., Wang, D., & Zen, K. (2014). MicroRNAs in Drug-induced Liver Injury. Journal of clinical and translational hepatology, 2(3), 162-9. https://doi.org/10.14218/JCTH.2014.00015
Li, Li-Min, et al. "MicroRNAs in Drug-induced Liver Injury." Journal of clinical and translational hepatology vol. 2,3 (2014): 162-9. doi: https://doi.org/10.14218/JCTH.2014.00015
Li LM, Wang D, Zen K. MicroRNAs in Drug-induced Liver Injury. J Clin Transl Hepatol. 2014 Sep;2(3):162-9. doi: 10.14218/JCTH.2014.00015. Epub 2014 Sep 15. PMID: 26357624; PMCID: PMC4521241.
Copy Download .nbib Format: NLM
Spontaneously reported haemorrhagic adverse events associated with rivaroxaban and dabigatran in Australia.

Therapeutic advances in drug safety

Chen EY, Diug B, Bell JS, Mc Namara KP, Dooley MJ, Kirkpatrick CM, McNeil JJ, Caughey GE, Ilomäki J.
PMID: 26834958
Ther Adv Drug Saf. 2016 Feb;7(1):4-10. doi: 10.1177/2042098615618171.

OBJECTIVES: The objective of our study was to describe spontaneously reported haemorrhagic adverse events associated with rivaroxaban and dabigatran in Australia.METHODS: Data were sourced from the Australian Therapeutic Goods Administration (TGA) Database of Adverse Event Notifications between June 2009...

Cite
Chen EY, Diug B, Bell JS, et al. Spontaneously reported haemorrhagic adverse events associated with rivaroxaban and dabigatran in Australia. Ther Adv Drug Saf. 2016;7(1):4-10doi: 10.1177/2042098615618171.
Chen, E. Y., Diug, B., Bell, J. S., Mc Namara, K. P., Dooley, M. J., Kirkpatrick, C. M., McNeil, J. J., Caughey, G. E., & Ilomäki, J. (2016). Spontaneously reported haemorrhagic adverse events associated with rivaroxaban and dabigatran in Australia. Therapeutic advances in drug safety, 7(1), 4-10. https://doi.org/10.1177/2042098615618171
Chen, Esa Y H, et al. "Spontaneously reported haemorrhagic adverse events associated with rivaroxaban and dabigatran in Australia." Therapeutic advances in drug safety vol. 7,1 (2016): 4-10. doi: https://doi.org/10.1177/2042098615618171
Chen EY, Diug B, Bell JS, Mc Namara KP, Dooley MJ, Kirkpatrick CM, McNeil JJ, Caughey GE, Ilomäki J. Spontaneously reported haemorrhagic adverse events associated with rivaroxaban and dabigatran in Australia. Ther Adv Drug Saf. 2016 Feb;7(1):4-10. doi: 10.1177/2042098615618171. PMID: 26834958; PMCID: PMC4716391.
Copy Download .nbib Format: NLM
Proton pump inhibitors and risk of readmission and mortality in older patients discharged from a tertiary hospital to residential aged care facilities.

Therapeutic advances in drug safety

Pegoli MA, Dedigama M, Mangoni AA, Russell PT, Grzeskowiak LE, Thynne T.
PMID: 28439400
Ther Adv Drug Saf. 2017 Apr;8(4):137-139. doi: 10.1177/2042098616679814. Epub 2016 Nov 29.

No abstract available.

Cite
Pegoli MA, Dedigama M, Mangoni AA, et al. Proton pump inhibitors and risk of readmission and mortality in older patients discharged from a tertiary hospital to residential aged care facilities. Ther Adv Drug Saf. 2016;8(4):137-139doi: 10.1177/2042098616679814.
Pegoli, M. A., Dedigama, M., Mangoni, A. A., Russell, P. T., Grzeskowiak, L. E., & Thynne, T. (2017). Proton pump inhibitors and risk of readmission and mortality in older patients discharged from a tertiary hospital to residential aged care facilities. Therapeutic advances in drug safety, 8(4), 137-139. https://doi.org/10.1177/2042098616679814
Pegoli, Matthew A, et al. "Proton pump inhibitors and risk of readmission and mortality in older patients discharged from a tertiary hospital to residential aged care facilities." Therapeutic advances in drug safety vol. 8,4 (2017): 137-139. doi: https://doi.org/10.1177/2042098616679814
Pegoli MA, Dedigama M, Mangoni AA, Russell PT, Grzeskowiak LE, Thynne T. Proton pump inhibitors and risk of readmission and mortality in older patients discharged from a tertiary hospital to residential aged care facilities. Ther Adv Drug Saf. 2017 Apr;8(4):137-139. doi: 10.1177/2042098616679814. Epub 2016 Nov 29. PMID: 28439400; PMCID: PMC5394504.
Copy Download .nbib Format: NLM
Risk of intracranial hypertension with intrauterine levonorgestrel: reply.

Therapeutic advances in drug safety

Etminan M.
PMID: 26834961
Ther Adv Drug Saf. 2016 Feb;7(1):25-6. doi: 10.1177/2042098615621264.

No abstract available.

Cite
Etminan M. Risk of intracranial hypertension with intrauterine levonorgestrel: reply. Ther Adv Drug Saf. 2016;7(1):25-6doi: 10.1177/2042098615621264.
Etminan, M. (2016). Risk of intracranial hypertension with intrauterine levonorgestrel: reply. Therapeutic advances in drug safety, 7(1), 25-6. https://doi.org/10.1177/2042098615621264
Etminan, Mahyar. "Risk of intracranial hypertension with intrauterine levonorgestrel: reply." Therapeutic advances in drug safety vol. 7,1 (2016): 25-6. doi: https://doi.org/10.1177/2042098615621264
Etminan M. Risk of intracranial hypertension with intrauterine levonorgestrel: reply. Ther Adv Drug Saf. 2016 Feb;7(1):25-6. doi: 10.1177/2042098615621264. PMID: 26834961; PMCID: PMC4716392.
Copy Download .nbib Format: NLM
Solifenacin linked QT interval prolongation and torsades de pointes.

Therapeutic advances in drug safety

Bray JJH, Hancox JC.
PMID: 28845232
Ther Adv Drug Saf. 2017 Jul;8(7):245-247. doi: 10.1177/2042098617702616. Epub 2017 Apr 10.

No abstract available.

Cite
Bray JJH, Hancox JC. Solifenacin linked QT interval prolongation and torsades de pointes. Ther Adv Drug Saf. 2017;8(7):245-247doi: 10.1177/2042098617702616.
Bray, J. J. H., & Hancox, J. C. (2017). Solifenacin linked QT interval prolongation and torsades de pointes. Therapeutic advances in drug safety, 8(7), 245-247. https://doi.org/10.1177/2042098617702616
Bray, Jonathan J H, and Hancox, Jules C. "Solifenacin linked QT interval prolongation and torsades de pointes." Therapeutic advances in drug safety vol. 8,7 (2017): 245-247. doi: https://doi.org/10.1177/2042098617702616
Bray JJH, Hancox JC. Solifenacin linked QT interval prolongation and torsades de pointes. Ther Adv Drug Saf. 2017 Jul;8(7):245-247. doi: 10.1177/2042098617702616. Epub 2017 Apr 10. PMID: 28845232; PMCID: PMC5564888.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 2125 entries